Prabhakar G, Mathur Anupam, Shunmugam G, Teje Y D, Sachdev S S, Sivaprasad N
Radiopharmaceuticals Program, Board of Radiation and Isotope Technology (BRIT), Sec. 20, Vashi, Navi Mumbai 400705, India.
Appl Radiat Isot. 2011 Jan;69(1):63-7. doi: 10.1016/j.apradiso.2010.08.020. Epub 2010 Oct 8.
[(131)I]-metaiodobenzylguanidine (mIBG) is a known radiopharmaceutical used for the treatment of neuroendocrine tumors. The development of therapeutic [(131)I]-mIBG doses at production level is highly challenging due to rapid product degradation and high radiation exposures to the production plant personnel. In the present work, a working module for the production of 10 doses (100 mCi each) in a single operation was developed following copper (I) assisted isotope exchange. The labeled product complies with the pharmaceutical specifications suitable for in-vivo patient use.
[131I] - 间碘苄胍（mIBG）是一种用于治疗神经内分泌肿瘤的放射性药物。由于产品快速降解以及生产工厂人员受到高辐射暴露，在生产水平上开发治疗性[131I] - mIBG剂量极具挑战性。在本工作中，通过铜（I）辅助同位素交换开发了一个单次操作生产10剂（每剂100毫居里）的工作模块。标记产品符合适用于患者体内使用的药品规格。
